Halberd Corporation2020-06-29T18:38:32-04:00

HALBERD CORPORATION

We’re A Medical Development Company Specializing in Breakthroughs for Serious Illnesses

PROVISIONAL PATENT APPLICATIONS

Welcome To Halberd Corporation

Halberd Corporation (HALB) is a publicly traded research-based company that intends to discover and develop medical treatments targeting the treatment of heretofore incurable and/or hard-to-cure diseases.

Halberd Corporation Fact Sheet

A brief review of some of Halberd’s significant accomplishments and recent developments.

PROPRIETARY SEQUENTIAL DIALYSIS TECHNIQUE

A methodology that physically removes the pathophysiologic basis of the disease

The Company’s proprietary Sequential Dialysis Technique is a methodology that physically removes the pathophysiologic basis of the disease, eliminating it without dangerous side effects.

  • Superior to current treatments which eliminate the presence of most illnesses but often with catastrophic or even fatal side effects.
  • Subtractive therapy (removal of harmful molecules) reduces risks associated with conventional “Additive” therapy (adding chemicals to the body).
  • Targets Cancer, Leukemia, Cockayne Syndrome, Neurofibromatosis, Fibromyalgia, Multiple Sclerosis, and Atherosclerosis – collectively over $700 billion market opportunity
PROPRIETARY PATENTED DRUG CANDIDATE

Feldetrex™

Developed a proprietary patented drug candidate, Feldetrex™ as a potential treatment for Fibromyalgia, neuropathic pain, and chemical addiction.

  • Expected to deliver significant relief to patients, while presenting fewer side effects than other alternate medications.
  • The annual market size of all proposed market segments for Feldetrex™ is over $20 billion
  • The company strategy is to use the sales of Feldetrex™ to provide short term revenue and to fund technology
Read More About Us

Latest News

Always Be in the Know with the Latest Halberd Corporation News